Eikonoklastes is a company headquartered in the United States.
Eikonoklastes is a biopharmaceutical company developing first-in-class gene therapies to treat neurodegenerative diseases, with initial focus on ALS using a gene therapy that overexpresses Caveolin-1 to provide neuroprotection.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.